Literature DB >> 9865805

Interferons in the treatment of multiple sclerosis: do they prevent the progression of the disease?

G Rice1, G Ebers.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9865805     DOI： 10.1001/archneur.55.12.1578

Source DB:  PubMed          Journal:  Arch Neurol        ISSN： 0003-9942


× No keyword cloud information.
  10 in total

1.  Disease modifying treatment in multiple sclerosis.

Authors:  G N Fuller; I Bone
Journal:  J Neurol Neurosurg Psychiatry       Date:  2001-12       Impact factor: 10.154

2.  Natural history of multiple sclerosis.

Authors:  G C Ebers
Journal:  J Neurol Neurosurg Psychiatry       Date:  2001-12       Impact factor: 10.154

Review 3.  Interferon in relapsing-remitting multiple sclerosis.

Authors:  G P Rice; B Incorvaia; L Munari; G Ebers; C Polman; R D'Amico; G Filippini
Journal:  Cochrane Database Syst Rev       Date:  2001

4.  Problems with UK government's risk sharing scheme for assessing drugs for multiple sclerosis.

Authors:  Cathie L M Sudlow; Carl E Counsell
Journal:  BMJ       Date:  2003-02-15

Review 5.  Comparative assessment of immunomodulating therapies for relapsing-remitting multiple sclerosis.

Authors:  Omar Khan; Rana Zabad; Christina Caon; Marina Zvartau-Hind; Alexandros Tselis; Robert Lisak
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

6.  Disability outcome measures in therapeutic trials of relapsing-remitting multiple sclerosis: effects of heterogeneity of disease course in placebo cohorts.

Authors:  C Liu; L D Blumhardt
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-04       Impact factor: 10.154

7.  A comparison of health utility measures for the evaluation of multiple sclerosis treatments.

Authors:  J D Fisk; M G Brown; I S Sketris; L M Metz; T J Murray; K J Stadnyk
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-01       Impact factor: 10.154

8.  Comparison of interferon beta products and azathioprine in the treatment of relapsing-remitting multiple sclerosis.

Authors:  M Etemadifar; M Janghorbani; V Shaygannejad
Journal:  J Neurol       Date:  2007-12-14       Impact factor: 4.849

Review 9.  Optimizing the initial choice and timing of therapy in relapsing-remitting multiple sclerosis.

Authors:  Rebecca S Farber; Ilana K Sand
Journal:  Ther Adv Neurol Disord       Date:  2015-09       Impact factor: 6.570

10.  Approved Beta interferons in relapsing-remitting multiple sclerosis: is there an odd one out?

Authors:  Alexis Clapin
Journal:  J Cent Nerv Syst Dis       Date:  2012-09-03
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.